Assessment of Phosphodiesterase Inhibitors in Alzheimer's Disease Experimental Models

Main Article Content

A. V. Chavda
V. M. Thorat
D. V. Sarvaiya

Abstract

Millions of people all over the globe suffer with AD. This complicated illness has a latency period of 20 years or more. Alzheimer's disease research has exploded in the past several decades, and finding a cure for this progressive neurological disease has become a global health priority. Despite this, modifying clinical symptoms of Alzheimer's disease and delaying the illness's start remains an important strategic aim, despite the persistent failure of drugs in clinical trials. In this publication, the authors evaluate phosphodiesterase inhibitors in animal models of Alzheimer's disease.

Article Details

How to Cite
Chavda , A. V. ., Thorat, V. M. ., & Sarvaiya, D. V. . (2023). Assessment of Phosphodiesterase Inhibitors in Alzheimer’s Disease Experimental Models. Journal of Coastal Life Medicine, 11(1), 2795–2804. Retrieved from https://www.jclmm.com/index.php/journal/article/view/760
Section
Articles

References

Yao L, Chen Y, Li J, et al. Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review and Meta-Analysis. Am J Alzheimers Dis Other Demen. 2018;33(5):283-296.

Singh AK, Kaur N, Chaudhary A, et al. Phosphodiesterase Inhibitors: A Novel Targeted Therapeutic Approach for Alzheimer's Disease. CurrNeuropharmacol. 2019;17(9):823-836.

Kroker KS, Brunner B, Bathke J, et al. Effect of phosphodiesterase inhibitors on cognitive function and cholinergic markers in a rat model of Alzheimer's disease. Behav Brain Res. 2018;347:441-447.

Chen F, Chen X, Yang D, et al. Inhibition of Phosphodiesterase-5 Improves Alzheimer's Disease-Related Phenotypes and Modulates Brain Indoleamine 2,3-Dioxygenases 1 /Tryptophan 2,3-Dioxygenases-Kynurenine Pathway Abnormalities in AβPP/PS1 Mice. Neurotherapeutics. 2019;16(4):1230-1243.

Oliveira LF, Goulart VA, Santos JR, et al. Phosphodiesterase-5 inhibition attenuates neuroinflammation and improves cognitive function in rats with induced Alzheimer's disease. J Neuroimmunol. 2017;305:90-98.

Shimizu-Albergine M, Rybalkin SD, Rybalkina IG, Feil R, Wolfsgruber W, Hofmann F. Individual roles of cyclic nucleotide phosphodiesterase isoforms in signal processing in mouse cerebellar granule cells. J Biol Chem. 2020;278(12):10508-10513.

Wang R, Li B, Li X, et al. PDE5 inhibitor sildenafil protects against ischemic stroke-induced neuroinflammation and cognitive impairment by suppressing peripheral and central immune responses. J Neuroinflammation. 2018;15(1):11.

Yu Y, Wang H, Peng G, et al. Phosphodiesterase 5 inhibitors attenuate neuroinflammation induced by middle cerebral artery occlusion in mice. Oncotarget. 2017;8(46):80817-80830.

Hendrix MJ, Sano M. Pharmacological treatments for Alzheimer's disease: beyond cholinesterase inhibitors. Aging Health. 2021;7(4):565-574.

Niewöhner J, Bohrmann B, Collin L, et al. AAV9-mediated central nervous system–targeted gene therapy for a mouse model of Niemann-Pick disease type A. Sci Transl Med. 2018;6.